Further research is vital to explore the long-term safety profile of IGBs, especially considering the evolving landscape of obesity management, which now includes pharmacological interventions like glucagon-like peptide-1 (GLP-1) analogs. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.